Drug Profile

NA 901

Alternative Names: NA-901

Latest Information Update: 17 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NeuroActiva
Class Antidementias; Antidepressants; Neuroprotectants
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I Major depressive disorder
Preclinical Alzheimer's disease

Most Recent Events

09 Sep 2024 NA 901 is still in preclinical trial for Alzheimer's disease in USA
09 Sep 2024 Phase-I clinical trials in Major depressive disorder (unspecified route) before September 2024
09 Sep 2024 Efficacy and adverse events data from a phase Ib trial in Major depressive disorder released by NeuroActiva

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com